Dr. Rosenthal has been continually funded by the NIH for the past 15 years to conduct bench to bedside translational studies in targeted therapy and molecular imaging. He has conducted over a dozen early phase clinical trials for diagnostic and therapeutic agents for the treatment of solid tumors. He is part of a multidisciplinary team of clinicians and basic scientists that perform preclinical and human studies to assesses near infrared fluorescent contrast agents for use in the operating room to make the cancer visible. The lab also focuses on molecular imaging of fluorescently labeled therapeutic antibodies to measure cellular delivery of therapies to tumors and adjacent tissues.